Efficacy and Safety of Rapid Titration Protocols of Lacosamide
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Three different dose titration schedules are tested to find a way to reduce the titration period of lacosamide
Full description
The investigators intend to find a way to reduce the titration period of lacosamide. Dosage of lacosamide is increased from 100-200 mg/d to 400 mg/d by three different titration schedule. Safety of lacosamide administration is primary endpoint. 50% responder rate (seizure reduction) and blood level of lacosamide are investigated for secondary endpoints.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adults aged 18-85 years old
- Patients diagnosed with focal epilepsy
- Patients subjected to the addition of lacosamide to treat focal onset seizures according to physician's judgement
- Subjects provided informed consent
Exclusion criteria
- Subjects who changed other antiepileptic drugs at the beginning of lacosamide treatment
- Subjects with unstable physical, mental or other disease condition that can impede with accurate evaluation or treatment
- Subjects with terminal illness or general medical condition that can impede with the participation of the clinical trial
- Subjects who do not agree with prior consent
Trial design
Primary purpose
Allocation
Interventional model
Masking
75 participants in 3 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal